New Zealand markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0800-0.0100 (-0.92%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 17.56M
Enterprise value -7.57M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.96
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.34

Trading information

Stock price history

Beta (5Y monthly) 2.13
52-week change 363.64%
S&P500 52-week change 328.64%
52-week high 31.6900
52-week low 30.4700
50-day moving average 31.1028
200-day moving average 31.1245

Share statistics

Avg vol (3-month) 351.36k
Avg vol (10-day) 356.46k
Shares outstanding 515.97M
Implied shares outstanding 615.97M
Float 813.89M
% held by insiders 16.86%
% held by institutions 130.06%
Shares short (29 Feb 2024) 410.78k
Short ratio (29 Feb 2024) 40.37
Short % of float (29 Feb 2024) 40.07%
Short % of shares outstanding (29 Feb 2024) 40.07%
Shares short (prior month 31 Jan 2024) 427.94k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-42.30%
Return on equity (ttm)-73.51%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -22.01M
Net income avi to common (ttm)-20.75M
Diluted EPS (ttm)-1.3000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)21.68M
Total cash per share (mrq)1.36
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.99
Book value per share (mrq)1.15

Cash flow statement

Operating cash flow (ttm)-17.75M
Levered free cash flow (ttm)-10.8M